Meeting
2016 ASCO Annual Meeting
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Authors
Adil Daud
University of California, San Francisco, San Francisco, CA
Adil Daud , Christian U. Blank , Caroline Robert , Igor Puzanov , Erika Richtig , Kim Allyson Margolin , Steven O'Day , Marta Nyakas , Jose Lutzky , Ahmad A. Tarhini , Elaine McWhirter , Christian Caglevic , Peter Mohr , Michael Millward , Marcus O. Butler , Honghong Zhou , Kenneth Emancipator , Scot Ebbinghaus , Nageatte Ibrahim , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT01866319
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9513)
DOI
10.1200/JCO.2016.34.15_suppl.9513
Abstract #
9513
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
First Author: Igor Puzanov
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown